Tenecteplase versus alteplase for patients with minor acute ischemic stroke: an analysis of the ORIGINAL clinical trial

This post hoc analysis of the ORIGINAL clinical trial demonstrates that tenecteplase (0.25 mg/kg) is a safe and effective alternative to alteplase (0.9 mg/kg) for treating patients with minor acute ischemic stroke, showing comparable rates of functional independence at 90 days and no significant differences in safety outcomes.

The Gist

The Big Picture: A Race Against Time

Imagine a stroke as a traffic jam in the brain's highway. A clot (a big truck) has blocked the road, cutting off the supply of oxygen to the brain cells.

For years, doctors have had one main tool to clear this jam: a drug called Alteplase. It's like a specialized tow truck that breaks up the blockage. However, it's a bit tricky to use; it needs to be pumped in slowly over an hour, like a slow drip.

Recently, a newer "tow truck" called Tenecteplase has arrived. It's faster (a single shot), more precise, and easier to use. But while we know it works well for big, scary traffic jams, doctors weren't 100% sure if it was the right choice for minor jams—cases where the symptoms seem small but could still cause long-term disability.

This study asked a simple question: For patients with "minor" strokes, is the new, fast tow truck (Tenecteplase) just as good as the old, slow one (Alteplase)?

---

The Experiment: The "ORIGINAL" Race

The researchers looked at data from a massive previous race called the ORIGINAL trial. They zoomed in specifically on the drivers who had minor strokes (defined as having a low score on a standard neurological test, like a "traffic severity meter" reading of 5 or less).

• The Players: They compared two groups of patients.
  • Group A: Got the new, fast drug (Tenecteplase).
  • Group B: Got the standard, slow drug (Alteplase).
• The Goal: To see who could get back to their normal life 90 days later without any major disability. Think of this as checking if the drivers could get back to work and play with their grandkids without needing a wheelchair or extra help.

The Results: A Dead Heat

After 90 days, the results were incredibly close. It was like a photo finish at a race where both cars crossed the line at almost the exact same time.

• Success Rate: About 86% of the people who got the new drug (Tenecteplase) recovered fully. About 83% of the people who got the old drug (Alteplase) recovered fully.
• The Verdict: Statistically, there was no real difference. The new drug worked just as well as the old one.
• Safety: Crucially, the new drug didn't cause any more "accidents" (bleeding in the brain) than the old one. Both were safe.

Why This Matters: The "Minor" Misconception

Here is the tricky part that this study helps clarify: Minor strokes are often ignored.

Imagine you have a flat tire. If your car is a giant truck, you stop immediately. But if it's a small scooter, you might think, "Eh, I can still ride it," and keep going. Many patients with minor strokes feel the same way. They might have a slight numbness in a finger or a tiny bit of weakness, so they don't rush to the hospital.

The Danger: Just because the stroke feels "minor" doesn't mean it's harmless. Without treatment, that small flat tire can turn into a total breakdown later, leaving the patient disabled.

This study tells us: Don't ignore the minor jams. If a patient has a minor stroke but it's "disabling" (meaning it stops them from doing what they usually do), they should get the clot-busting drug. And now, we know they can get the new, faster drug (Tenecteplase) with the same confidence as the old one.

The Takeaway

Think of Tenecteplase as the express delivery service and Alteplase as the standard mail service.

For a long time, we only knew the express service worked for heavy, urgent packages (severe strokes). This study proves that the express service works just as well for the smaller, lighter packages (minor strokes) too.

In simple terms:

1. Don't skip treatment for minor strokes if they affect your daily life.
2. Tenecteplase is a great alternative to the standard drug. It's faster to give and just as effective.
3. The future looks bright: Doctors now have a faster, easier tool to help more people recover from strokes, even the "small" ones.

Technical Summary

1. Problem Statement

• Clinical Context: Acute ischemic stroke (AIS) often presents with mild neurological deficits (minor stroke). Despite guidelines recommending intravenous thrombolysis (IVT) within 4.5 hours for patients with disabling minor symptoms, these patients are frequently overlooked for treatment due to the mildness of symptoms, leading to preventable residual disability.
• Therapeutic Gap: While Tenecteplase (TNK) is increasingly endorsed as an alternative to the standard Alteplase (ALP) for AIS due to its pharmacological advantages (single bolus, longer half-life), there is insufficient evidence regarding its specific efficacy and safety in the minor stroke population (defined as NIHSS ≤ 5) within the standard 4.5-hour window.
• Objective: To evaluate the efficacy and safety of Tenecteplase (0.25 mg/kg) versus Alteplase (0.9 mg/kg) specifically in patients with minor disabling acute ischemic stroke using data from the phase 3 ORIGINAL randomized clinical trial.

2. Methodology

• Study Design: This is a post hoc analysis of the ORIGINAL randomized clinical trial (NCT04915729), a multicenter, active-controlled, parallel-group, randomized, open-label, blinded-endpoint trial conducted in China.
• Population:
  • Source: 596 patients from the full ORIGINAL analysis set (N=1465) were selected.
  • Inclusion Criteria: Patients with AIS, symptom onset <4.5 hours, and a National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.
  • Specific Definition of Minor Stroke:
    • NIHSS < 4 plus a measurable motor deficit (arms or legs) of ≥ 1 point (indicating "disabling" symptoms).
    • OR NIHSS 4–5 (no additional motor requirement).
• Intervention:
  • Tenecteplase Group (n=299): 0.25 mg/kg IV bolus over 5–10 seconds.
  • Alteplase Group (n=297): 0.9 mg/kg IV (10% bolus, remainder infused over 1 hour).
• Primary Outcome: Proportion of patients achieving a modified Rankin Scale (mRS) score of 0 or 1 (no symptoms or no significant disability) at Day 90.
• Secondary Outcomes:
  • Efficacy: Major neurological improvement at 24h, mRS 0–2 at Day 90, change in NIHSS from baseline to Day 90, mRS distribution, Barthel Index ≥95.
  • Safety: Symptomatic intracerebral hemorrhage (sICH) per ECASS III criteria, 90-day all-cause mortality, and mRS 5 or 6 at Day 90.
• Statistical Analysis:
  • Primary outcome analyzed via log-binomial regression adjusted for baseline NIHSS, age, and time to drug administration.
  • Results reported as Risk Ratios (RR) with 95% Confidence Intervals (CI).
  • Subgroup analyses performed for NIHSS, time to treatment, sex, age, atrial fibrillation, diabetes, and thrombectomy status.
  • Significance threshold: Two-sided p < 0.05 (noted as exploratory due to multiple testing).

3. Key Contributions

• Subgroup Specificity: Provides the first robust head-to-head comparison of TNK vs. ALP specifically tailored to the minor disabling stroke subgroup (NIHSS ≤ 5) within a large Phase 3 trial.
• Definition Refinement: Clarifies the operational definition of "disabling" minor stroke by requiring measurable motor deficits in patients with low NIHSS scores (<4), addressing the ambiguity often found in clinical practice.
• Safety Validation: Confirms that the safety profile of Tenecteplase in minor stroke is comparable to Alteplase, specifically regarding the critical risk of symptomatic intracerebral hemorrhage (sICH).
• Generalizability: The study population mirrors real-world Chinese stroke registry data, suggesting findings are applicable to the broader Asian and potentially global minor stroke population.

4. Key Results

• Primary Efficacy (Day 90 mRS 0–1):
  • Tenecteplase: 86.3% (258/299)
  • Alteplase: 82.8% (246/297)
  • Result: Risk Ratio (RR) = 1.04 [95% CI 0.971–1.114]. No statistically significant difference was observed, though the point estimate favored Tenecteplase.
• Secondary Efficacy:
  • No significant differences were found in major neurological improvement at 24h, mRS 0–2, Barthel Index, or NIHSS change.
  • Point estimates for all secondary efficacy outcomes favored Tenecteplase (RRs ranging from 1.03 to 1.13), but confidence intervals crossed 1.0.
• Safety Outcomes:
  • sICH: Identical rates in both groups (1.7% or 5 patients each). RR = 1.00 [95% CI 0.276–3.648].
  • 90-Day Mortality: 2.3% (Tenecteplase) vs. 2.7% (Alteplase). RR = 0.88 [95% CI 0.322–2.390].
  • Severe Disability/Death (mRS 5–6): 3.3% vs. 3.4%.
• Subgroup Analysis: No heterogeneity of treatment effect was observed across predefined subgroups (age, sex, NIHSS strata, comorbidities, time to treatment).

5. Significance and Conclusion

• Clinical Implication: The study demonstrates that Tenecteplase 0.25 mg/kg is non-inferior and comparable to Alteplase 0.9 mg/kg for patients with minor disabling acute ischemic stroke.
• Treatment Selection: Given Tenecteplase's logistical advantages (single bolus administration) and pharmacological profile, it is a suitable alternative to Alteplase for this specific patient population.
• Risk-Benefit Profile: The low rates of sICH (1.7%) and mortality (~2.5%) in both groups reinforce that IVT is safe and effective for minor disabling strokes, potentially encouraging clinicians to treat patients who might otherwise be excluded due to "mild" symptoms.
• Limitations: As a post hoc analysis, the study was not powered for non-inferiority testing of this specific subgroup. The sample size for certain subgroups was small, and the results should be interpreted as exploratory. No data was available for large vessel occlusion (LVO) or stroke mimics within this specific minor stroke cohort.

Final Verdict: Tenecteplase offers a comparable efficacy and safety profile to Alteplase for minor disabling strokes, supporting its use as a preferred alternative in clinical settings where logistical simplicity is advantageous.